Advantage Alpha Capital Partners LP Trims Stock Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Advantage Alpha Capital Partners LP lessened its position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 71.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 101,558 shares of the company’s stock after selling 256,896 shares during the quarter. Advantage Alpha Capital Partners LP owned 0.08% of Organogenesis worth $290,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of Organogenesis by 11.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 50,951 shares of the company’s stock worth $145,000 after purchasing an additional 5,359 shares during the period. Caxton Associates LP acquired a new stake in Organogenesis during the 1st quarter valued at approximately $88,000. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Organogenesis by 349.1% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 186,236 shares of the company’s stock valued at $529,000 after acquiring an additional 144,771 shares during the last quarter. CWM LLC boosted its holdings in shares of Organogenesis by 301.8% in the 2nd quarter. CWM LLC now owns 25,617 shares of the company’s stock valued at $72,000 after acquiring an additional 19,242 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in shares of Organogenesis by 309.3% in the second quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company’s stock worth $11,136,000 after acquiring an additional 3,005,450 shares during the period. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Price Performance

NASDAQ ORGO opened at $3.96 on Wednesday. Organogenesis Holdings Inc. has a 1 year low of $2.16 and a 1 year high of $4.70. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The company has a fifty day moving average of $3.21 and a 200 day moving average of $2.91.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The business had revenue of $115.18 million during the quarter, compared to analysts’ expectations of $109.59 million. During the same quarter in the previous year, the firm posted $0.02 EPS. On average, research analysts anticipate that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.